Acute lymphatic leukemia in adults: Diagnosis, high-risk groups and treatment;Akute lymphatische leukämie des erwachsenen: Diagnostik, risikogruppen und therapie

Internist

Volumn 43, Issue 10, 2002, Pages 1212-1227

  Hoelzer, D ^a,b   Arnold, R ^a   Bartram, C R ^a   Bohme A ^a   Freund, M ^a   Ganser, A ^a   Kneba, M ^a   Lipp, T ^a   Ludwig, W D ^a   Maschmeyer, G ^a   Rieder, H ^a   Thiel, E ^a   Messerer, D ^a   Weiss, A ^a   Gokbuget N ^a  

^a Akute Lymphatische Leukämie des Erwachsenen ^*  (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ASPARAGINASE; ASPARAGINASE MACROGOL; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TIOGUANINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER RISK; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; REVIEW; SYMPTOM; ADULT; BLOOD CELL; BONE MARROW; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; CLASSIFICATION; GENETICS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RISK; SKULL IRRADIATION; STEM CELL TRANSPLANTATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; BONE MARROW; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; RISK; STEM CELL TRANSPLANTATION;

EID: 0036824960     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-002-0702-x     Document Type: Review

References (40)

1. Annino L, Vegna ML, Camera A et al. (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow- up of the GIMEMA ALL 0288 randomized study. Blood 99: 863-871
2. Arnold R, Massenkeil G, Beelen DW et al. (2000) Nonmyeloablative stem cell transplantation in adults with high-risk ALL. Blood 96: 351a
3. Atta J, Fauth F, Keyser M et al. (2000) Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction. Bone Marrow Transplant 25: 97-104
4. Bene MC, Castoldi G, Knapp W et al. (1995) Proposal for the immunological classification of acute leukemias. Leukemia 9: 1783-1786
5. Brueggemann M, Droese J, Raff T et al. (2001) The prognostic significance of minimal residual disease in adult standard risk patients with acute lymphoblastic leukemia. Blood 98: 314a
6. Brueggemann M, Droese J, Scheuring U et al. (2001) Minimal residual disease in adult patients with acute lymphoblastic leukemia during the first year of therapy predicts clinical outcome. Hematol J 1 (Suppl): 700a
7. Bunjes D, Duncker C, Seitz U et al. (1998) Intensification of the conditioning regimen for high-risk leukaemia with a 188Re-labelled anti-CD 164b monoclonal antibody: results of feasibility study. Blood 92 (Suppl): 4471a
8. Campana D. (1997) Immunophenotypic analysis in the monitoring of minimal residual disease. Rev Clin Exp Hematol 1: 42-56
9. Cavé H, Van der Werff Ten Bosch J, Suciu S et al. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 339: 591-598
10. Cornelissen JJ, Carston M, Kollman C et al. (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97: 1572-1577
11. Coustan-Smith E, Sancho J, Hancock ML et al. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96: 2691-2696
12. Durrant IJ, Prentice HG, Richards SM (1997) Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research council randomized trial UKALL XA. Br J Haematol 99: 84-92
13. Faderl S, Kantarjian HM, Talpaz M, Estrov Z (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91: 3995-4019
14. Foroni L, Harrison CJ, Hoffbrand AV, Potter MN (1999) Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol 105: 7-24
15. Gleissner B, Gökbuget N, Bartram CR et al. (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99: 1536-1543
16. Gökbuget N, Arnold R, Buechner T et al. (2001) Intensification of induction and consolidation improves only subgroups of adult ALL: Analysis of 1200 patients in GMALL study 05/93. Blood 98: 802a
17. Gökbuget N, de Wit M, Gerhardt A et al. (2000) Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia. Blood 96
18. Gökbuget N, Hoelzer D (1998) Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J Neuro Oncol 38: 167-180
19. Gökbuget N, Hoelzer D, Arnold R et al. (2000) Treatment of adult ALL according to thepProtocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 14: 1307-1325
20. Griesinger F, Falk M, Pirò-Noack M et al. (1994) Leukemia associated expression patterns of differentiation antigens in acute lymphoblastic leukemia for monitoring of minimal residual disease by multiparameter flow cytometry. Blood 84 (Suppl): 300a
21. Hoelzer D, Arnold R, Freund M et al. (1999) Characteristics, outcome and risk factors in adult T-lineage acute lymphoblastic leukemia (ALL) Blood 94 (Suppl): 2926a
22. Hoelzer D, Gökbuget N (2000) New approaches in acute lymphoblastic leukemia in adults: Where do we go? Semin Oncol 27: 540-559
23. Hoelzer D, Gökbuget N (2000) Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 36: 49-58
24. Hoelzer D, Gökbuget N, Brüggemann M et al. (2001) Clinical impact of minimal residual disease (MRD) in trial design for adult ALL. Blood 98: 584a
25. Hoelzer D, Gökbuget N, Digel W et al. (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia (ALL). Blood 99: (in press)
26. Hoelzer D, Ludwig WD, Thiel E et al. (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87: 495-508
27. Hoelzer D, Thiel E, Ludwig WD et al. (1993) Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). Leukemia Suppl 2: 130-134
28. Kantarjian HM, O'Brien S, Smith TL et al. (2000) Results of treatment with hyper-CVAD, a doseintensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18: 547-561
29. Krackhardt A, Schwartz S, Thiel E (2000) Targeting folates by Carboxypeptidase G2: Potential applications in anticancer therapy. Onkologie 23: 538-543
30. Larson RA, Dodge RK, Burns CP et al. (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 85: 2025-2037
31. Larson RA, Dodge RK, Linker CA et al. (1998) A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92: 1556-1564
32. Löffler H, Gassmann W (1994) Morphology and cytochemistry of acute lymphoblastic leukemia. Baillieres Clin Haematol 7: 263
33. Ludwig WD, Rieder H, Bartram CR et al. (1998) Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 92: 1898-1909
34. Ludwig WD, Raghavachar A, Thiel E (1994) Immunophenotypic classification of acute lymphoblastic leukemia. Baillieres Clin Haematol 7: 235
35. Mandelli F, Annino L, Rotoli B et al. (1996) The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. Br J Haematol 92: 665-672
36. Ottmann OG, Druker B, Sawyers CL et al. (2002) A phase II study of Imatinib Mesylate (Glivec) in patients with relapsed or erfractory philadelphia-chromosome-positive acute lymphoid leukemias. Blood (in press, prepublished online, May 17,2002)
37. Rowe JM, Richards S, Wiernik PH et al. (1999) Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): Early results from the international ALL trial (MRC UKALL/ECOG E2993) Blood 94 (Suppl): 732a
38. Scheuring U, Pfeifer H, Brueck H et al. (2001) Prognostic relevance of minimal residual disease (MRD) analysis in BCR-ABL positive acute lymphoblastic leukemia (ALL) patients during Gleevec (STI571) therapy. Blood 98: 762a
39. Thiebaut A, Vernant JP, Degos L et al. (2000) Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 14: 1353-1366
40. van Dongen JJ, Seriu T, Panzer-Grümayer ER et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352: 1731-1738